Cancer research

Accelerating Research to Improve Health

The UCSF Clinical and Translational Science Institute (CTSI) is part of the Clinical and Translational Science Award (CTSA) program funded by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) (Grant Number UL1 TR001872). The content of this website is solely the responsibility of CTSI and does not necessarily represent the official views of the NIH.

Cite CTSI NIH Funding Acknowledgment: Important — All publications resulting from the utilization of CTSI resources are required to credit the CTSI grant by including the NIH Funding acknowledgment and must comply with NIH Public Access Policy.

To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.

Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer.

Immunotherapeutic targeting and PET imaging of DLL3 in small cell neuroendocrine prostate cancer.

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.

Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.

Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

A very long-acting Poly(ADP-ribose) polymerase inhibitor suppresses cancer cell growth in DNA repair-deficient tumor models.

Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma.

Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.

Pages

Search form

You are here

Cancer research

Pages